SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Report 3.5% Beneficial Ownership in Blueprint Medicines Corp.
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 3.5% beneficial ownership stake in Blueprint Medicines Corp. as of December 31, 2024.
Summary
- FMR LLC and Abigail P. Johnson jointly reported beneficial ownership of 2,247,678.51 shares of Blueprint Medicines Corp. common stock.
- This ownership represents 3.5% of the total outstanding common stock of Blueprint Medicines Corp.
- The filing is an Amendment No. 4 to a Schedule 13G, indicating a passive investment position.
- FMR LLC, a Delaware-organized entity, holds sole voting power over 2,244,164.00 shares and sole dispositive power over 2,247,678.51 shares.
- Abigail P. Johnson, a U.S. citizen, holds sole dispositive power over 2,247,678.51 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Blueprint Medicines Corp.
- The filing identifies several FMR LLC subsidiaries and affiliates that beneficially own shares, including FIAM LLC (Investment Adviser), Fidelity Institutional Asset Management Trust Company (Bank), Fidelity Management & Research Company LLC (Investment Adviser), and Strategic Advisers LLC (Investment Adviser).
- Members of the Johnson family, including Abigail P. Johnson, are the predominant owners of FMR LLC's Series B voting common shares (representing 49% of voting power) and may be deemed to form a controlling group with respect to FMR LLC under the Investment Company Act of 1940.
Sentiment
Score: 5
Explanation: The document is a standard beneficial ownership filing (Schedule 13G) and does not contain information that would typically indicate positive or negative sentiment regarding the issuer's performance or prospects. It merely reports a passive ownership stake.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| January 3, 2023 | Effective date of Power of Attorney for FMR LLC. |
| January 10, 2023 | Date of Schedule 13G filing by FMR LLC where its Power of Attorney was incorporated by reference. |
| January 26, 2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| January 31, 2023 | Date of Schedule 13G filing by FMR LLC where Abigail P. Johnson's Power of Attorney was incorporated by reference. |
| December 31, 2024 | Date of event which requires the filing of this statement (reporting period end). |
| February 11, 2025 | Date of filing and signature for this Schedule 13G Amendment No. 4. |
Keywords
Blueprint Medicines Corp, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.